Literature DB >> 33819718

Evidence-based recommendations on categories for extent of resection in diffuse glioma.

Philipp Karschnia1, Michael A Vogelbaum2, Martin van den Bent3, Daniel P Cahill4, Lorenzo Bello5, Yoshitaka Narita6, Mitchel S Berger7, Michael Weller8, Joerg-Christian Tonn9.   

Abstract

Surgical resection represents the standard of care in diffuse glioma, and more extensive tumour resection appears to be associated with favourable outcome. Up to now, terminology to describe extent of resection has been inconsistently applied across clinical trials which hampers comparative analysis of cohorts between different studies. Based on a comprehensive literature review, we developed evidence-based expert recommendations on categories for extent of resection. Recommendations are formulated for the categories 'biopsy', 'partial resection', 'subtotal resection', 'near total resection', 'complete resection' and 'supramaximal resection'. Definitions rest on reduction of contrast- and non-contrast-enhancing tumour in glioblastoma, and on reduction of T2/FLAIR-hyperintense tumour in gliomas WHO grade 2 or 3. Both relative reduction of tumour volume (in percentage) as a measurement of surgical efficacy and absolute residual tumour volume (in cm3) as a measurement of remaining tumour burden are incorporated into the categories for extent of resection. Class of evidence for the proposed categories ranges from class IIB to IV. Limitations of the suggested categories are discussed. The proposed categories on extent of resection offer a framework to standardize nomenclature based on previous studies, and will need to be evaluated in prospective, molecularly well-defined cohorts. Our categories may eventually help as a stratification factor for future clinical trials.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Diffuse glioma; Extent of resection; Glioblastoma; MRI; Nomenclature; Surgical resection

Year:  2021        PMID: 33819718     DOI: 10.1016/j.ejca.2021.03.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

1.  The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study.

Authors:  Tamara Ius; Sam Ng; Jacob S Young; Barbara Tomasino; Maurizio Polano; David Ben-Israel; John J P Kelly; Miran Skrap; Hugues Duffau; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

Review 2.  Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic.

Authors:  Francesco Guerrini; Elena Roca; Giannantonio Spena
Journal:  Brain Sci       Date:  2022-05-16

3.  KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma.

Authors:  Yifan Yuan; Biao Yang; Zengxin Qi; Zhenyuan Han; Jiajun Cai; Jianping Song
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

4.  Survival and functional outcomes in paediatric thalamic and thalamopeduncular low grade gliomas.

Authors:  Vladimír Beneš; Michal Zápotocký; Petr Libý; Jakub Táborský; Jana Blažková; Jana Blažková; David Sumerauer; Adéla Mišove; Ivana Perníková; Martin Kynčl; Lenka Krsková; Miroslav Koblížek; Josef Zámečník; Ondřej Bradáč; Michal Tichý
Journal:  Acta Neurochir (Wien)       Date:  2022-01-19       Impact factor: 2.216

5.  Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge.

Authors:  Vittorio Stumpo; Martina Sebök; Christiaan Hendrik Bas van Niftrik; Katharina Seystahl; Nicolin Hainc; Zsolt Kulcsar; Michael Weller; Luca Regli; Jorn Fierstra
Journal:  MAGMA       Date:  2021-12-07       Impact factor: 2.310

6.  Resection of glioma-Feeding the beast?

Authors:  Jens Blobner; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

7.  Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma.

Authors:  Peter H Yang; Yu Tao; Jingqin Luo; Mounica Paturu; Hsiang-Chih Lu; Shakti Ramkissoon; Jonathan W Heusel; Eric C Leuthardt; Michael R Chicoine; Joshua L Dowling; Gavin P Dunn; Eric Duncavage; Sonika Dahiya; Arindam R Chattherjee; Albert H Kim
Journal:  Neurooncol Adv       Date:  2022-01-10

8.  Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?

Authors:  Nico Teske; Philipp Karschnia; Jonathan Weller; Sebastian Siller; Mario M Dorostkar; Jochen Herms; Louisa von Baumgarten; Joerg Christian Tonn; Niklas Thon
Journal:  J Neurooncol       Date:  2021-12-13       Impact factor: 4.130

9.  Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults.

Authors:  Alessandro Moiraghi; Alexandre Roux; Sophie Peeters; Jean-Baptiste Pelletier; Marwan Baroud; Bénédicte Trancart; Catherine Oppenheim; Emmanuèle Lechapt; Chiara Benevello; Eduardo Parraga; Pascale Varlet; Fabrice Chrétien; Edouard Dezamis; Marc Zanello; Johan Pallud
Journal:  Cancers (Basel)       Date:  2021-06-10       Impact factor: 6.575

Review 10.  Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers.

Authors:  Clara Guido; Clara Baldari; Gabriele Maiorano; Angela Mastronuzzi; Andrea Carai; Concetta Quintarelli; Biagio De Angelis; Barbara Cortese; Giuseppe Gigli; Ilaria Elena Palamà
Journal:  Diagnostics (Basel)       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.